Oleander poisoning: Two cases with contrasting cardiac presentations.

Australas Emerg CareNov 17, 2025 (epub)
Case ReportEmergency MedicineCardiology

Steven Kelly, Dushan Jayaweera, Naren Gunja

✦ AI-curated · Sources linked

Case in brief

Two family members presented after intentionally ingesting oleander leaves as a food source. The report describes differing cardiac presentations in the two patients, with oleander toxicity diagnosed and both patients successfully managed. The abstract does not specify their individual symptoms, cardiac findings, diagnostic tests, or treatments.

What made this case unusual

The same ingestion context was associated with contrasting cardiac presentations in two family members.

Diagnostic / clinical pearl

Oleander ingestion can cause life-threatening cardiac and gastrointestinal complications; consider it when assessing a patient with a relevant plant-ingestion history.

Source

PubMed · PMID 41253646

Published in Australas Emerg Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.